论文部分内容阅读
目的:观察噻托溴铵联合吸入布地奈德/福莫特罗对轻中度老年支气管哮喘患者的临床疗效。方法:65例老年男性支气管哮喘患者,随机分为两组:观察组(噻托溴铵+布地奈德/福莫特罗):吸入噻托溴铵干粉剂(18ug,每日1次)与布地奈德/福莫特罗干粉剂(160/4.5μg,每日2次);对照组(布地奈德/福莫特罗):吸入布地奈德/福莫特罗干粉剂(160/4.5μg,每日2次)。治疗前及治疗后24w及48w,分别比较两组患者肺功能变化。结果:治疗24w后,与治疗前比较,观察组FEV1/预计值差异有统计学意义(P<0.05);治疗48w后,与治疗前比较,两组肺功能均明显改善,差异均有统计学意义(P<0.05),两组组间比较,观察组高于对照组,FEV1/预计值差异有统计学意义(P<0.05)。结论:对于有长期吸烟史的轻中度老年支气管哮喘患者,在吸入糖皮质激素和长效β2受体激动剂的基础上加用噻托溴铵,可明显改善肺功能。
Objective: To observe the clinical efficacy of tiotropium combined inhalation of budesonide and formoterol in patients with mild to moderate bronchial asthma. Methods: Sixty-five elderly male patients with bronchial asthma were randomly divided into two groups: observation group (tiotropium + budesonide / formoterol): tiotropium powder inhalation (18ug once daily) Budesonide / formoterol dry powder (160/4.5 μg twice daily); control group (budesonide / formoterol): inhaled budesonide / formoterol dry powder (160 / 4.5 μg, 2 times a day). Before and after treatment and 24w and 48w after treatment, pulmonary function changes were compared between the two groups. Results: After treatment for 24 weeks, the FEV1 / predictive value in the observation group was significantly different from that before treatment (P <0.05); after 48 weeks of treatment, the lung function of both groups was significantly improved after treatment, the differences were statistically significant (P <0.05). The comparison between the two groups showed that the observation group was higher than the control group, and the difference of FEV1 / predicted value was statistically significant (P <0.05). CONCLUSIONS: For patients with mild-to-moderate elderly bronchial asthma who have a long history of smoking, adding tiotropium to inhaled glucocorticoids and long-acting beta 2 agonists significantly improves lung function.